Patents by Inventor Timothy C Thompson
Timothy C Thompson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130209962Abstract: Systems and processes for the duplication of dentures from existing dentures. The interior and exterior of the dentures are scanned and a best fit procedure is used to create a fully digitized denture. The denture teeth are selected from a library that is the closest fit to the original denture teeth. The library teeth are offset a preset distance to compensate for the best fit. The teeth are then subtracted from the digitized denture. The margins of the denture are then cleaned after subtracting the teeth. The denture base is then ready for manufacturing. The teeth are then installed onto the denture base and provided to the patient.Type: ApplicationFiled: November 3, 2011Publication date: August 15, 2013Applicant: Global Dental Science, LLCInventors: Timothy C. Thompson, Scott C. Keating, Andrzej J. Jakson
-
Patent number: 7824685Abstract: This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response.Type: GrantFiled: January 19, 2005Date of Patent: November 2, 2010Assignee: Baylor College of MedicineInventors: Timothy C. Thompson, Chengzhen Ren
-
Patent number: 7723475Abstract: The invention is directed to purified and isolated novel RGL2 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: August 31, 2005Date of Patent: May 25, 2010Assignee: Baylor College of MedicineInventors: Timothy C. Thompson, Chenghui Ren, Chengzhen Ren
-
Patent number: 7666412Abstract: The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.Type: GrantFiled: October 22, 2003Date of Patent: February 23, 2010Assignee: Baylor College of MedicineInventor: Timothy C. Thompson
-
Patent number: 7645452Abstract: This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response.Type: GrantFiled: April 17, 2003Date of Patent: January 12, 2010Assignee: Baylor College of MedicineInventors: Timothy C. Thompson, Chengzhen Ren
-
Patent number: 7601806Abstract: The invention is directed to purified and isolated novel RGL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.Type: GrantFiled: June 8, 2004Date of Patent: October 13, 2009Assignee: Baylor College of MedicineInventors: Timothy C. Thompson, Chenghui Ren, Chengzhen Ren
-
Patent number: 7462491Abstract: Serum cav-1 is disclosed as a biomarker for prostate cancer that has the power to differentiate between prostate cancer and BPH patients.Type: GrantFiled: September 15, 2004Date of Patent: December 9, 2008Assignee: Baylor College of MedicineInventor: Timothy C. Thompson
-
Patent number: 7029859Abstract: The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.Type: GrantFiled: March 5, 2001Date of Patent: April 18, 2006Assignee: Baylor College of MedicineInventor: Timothy C. Thompson
-
Patent number: 6949109Abstract: A surgical scalpel having a replaceable, spring-actuated, retractable cutting blade which may be locked in the operating or deployed position and returned to its safety position using a single digit on one hand.Type: GrantFiled: August 22, 2003Date of Patent: September 27, 2005Assignee: Innovative Surgical Technology, Inc.Inventors: Mark L. Iske, Timothy C. Thompson, Charles T. Gregg
-
Publication number: 20040111106Abstract: A surgical scalpel having a replaceable, spring-actuated, retractable cutting blade which may be locked in the operating or deployed position and returned to its safety position using a single digit on one hand.Type: ApplicationFiled: August 22, 2003Publication date: June 10, 2004Inventors: Mark L. Iske, Timothy C. Thompson, Charles T. Gregg
-
Publication number: 20040018173Abstract: The invention relates to methods for the isolation of metastatic sequences and the isolated sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to cancer. Treated cells are implanted in an animal and incubated for a period of time sufficient for the cells to proliferate and develop malignant transplants. RNA from the malignant transplant and the primary tumor are analyzed by differential display polymerase chain reaction. Differentially expressed genes are cloned, reanalyzed, and sequenced. These genes and sequences can be used as probes in the diagnosis of neoplastic disorders, as probes to isolate metastatic sequences and as a therapeutic agent in the treatment of neoplastic disorders. The metastatic sequence may be a dominant metastatic sequence or a recessive metastatic sequence.Type: ApplicationFiled: April 7, 2003Publication date: January 29, 2004Applicant: Baylor College of MedicineInventors: Timothy C. Thompson, Chengzhen Ren
-
Publication number: 20040009508Abstract: This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response.Type: ApplicationFiled: April 17, 2003Publication date: January 15, 2004Applicant: Baylor College of MedicineInventors: Timothy C. Thompson, Chengzhen Ren
-
Publication number: 20030224464Abstract: Prostate cancer cells secrete cav-1 and that secreted cav-1 can stimulate viability and clonal growth in prostate cancer cells that do not express cav-1. The concept of a secreted autocrine or paracrine factor that directly contributes to androgen resistance in prostate cancer is novel and represents an efficient mechanism for maximizing resistance to various pro-apoptotic stimuli that metastatic cells often encounter during the highly inefficient process of metastasis. The detection of secreted cav-1 in patient sera has significant potential for clinical utility. Since, unlike PSA, secreted cav-1 is linked to malignant characteristics of prostate cancer cells, serum cav-1 has a unique prognostic and diagnostic capacity. The levels of cav-1 protein within prostate cancer tissues were evaluated directly using immunohistochemistry and RT-PCR as well as serum cav-1 levels in men who undergo radical prostatectomy with lymph node dissection.Type: ApplicationFiled: January 31, 2003Publication date: December 4, 2003Applicant: Baylor College of MedicineInventor: Timothy C. Thompson
-
Publication number: 20030125335Abstract: A method for treating or preventing a BPH in a mammal which comprises administering to said mammal an amount of a drug, comprising an &agr;1-adrenoreceptor antagonist or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing the BPH.Type: ApplicationFiled: February 18, 2003Publication date: July 3, 2003Applicant: Pfizer Inc.Inventors: Timothy C. Thompson, Guang Yang, Michael G. Wyllie
-
Patent number: 6545139Abstract: The invention relates to methods for the isolation of metastatic sequences and the isolated sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to cancer. Treated cells are implanted in an animal and incubated for a period of time sufficient for the cells to proliferate and develop malignant transplants. RNA from the malignant transplant and the primary tumor are analyzed by differential display polymerase chain reaction. Differentially expressed genes are cloned, reanalyzed, and sequenced. These genes and sequences can be used as probes in the diagnosis of neoplastic disorders, as probes to isolate metastatic sequences and as a therapeutic agent in the treatment of neoplastic disorders. The metastatic sequence may be a dominant metastatic sequence or a recessive metastatic sequence.Type: GrantFiled: March 12, 1999Date of Patent: April 8, 2003Assignee: Baylor College of MedicineInventors: Timothy C. Thompson, Chengzhen Ren
-
Publication number: 20030003103Abstract: The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.Type: ApplicationFiled: May 21, 2002Publication date: January 2, 2003Inventor: Timothy C. Thompson
-
Publication number: 20020052025Abstract: This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response.Type: ApplicationFiled: June 8, 2001Publication date: May 2, 2002Inventors: Timothy C. Thompson, Chengzhen Ren
-
Publication number: 20010012890Abstract: The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.Type: ApplicationFiled: March 5, 2001Publication date: August 9, 2001Inventor: Timothy C. Thompson
-
Patent number: RE38392Abstract: The invention relates to methods for the identification of metastatic sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to metastasis. Treated cells are implanted in an animal of at a primary site and incubated for a period of time sufficient for the cells to proliferate and develop metastases at secondary sites. Expressed sequences from cells at the primary and secondary sites are amplified by differential display polymerase chain reaction and compared. Differentially expressed sequences are identical identified and can be cloned and sequenced. These sequences can be used as probes in the diagnosis of metastatic disorders, as probes to isolate metastatic sequences and as a therapeutic agent.Type: GrantFiled: November 6, 2001Date of Patent: January 20, 2004Assignee: Baylor College of MedicineInventor: Timothy C. Thompson
-
Patent number: RE38490Abstract: The invention relates to methods for the identification of metastatic sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to metastasis. Treated cells are implanted in an animal of at a primary site and incubated for a period of time sufficient for the cells to proliferate and develop metastases at secondary sites. Expressed sequences from cells at the primary and secondary sites are amplified by differential display polymerase chain reaction and compared. Differentially expressed sequences are identical identified and can be cloned and sequenced. These sequences can be used as probes in the diagnosis of metastatic disorders, as probes to isolate metastatic sequences and as a therapeutic agent.Type: GrantFiled: October 16, 2001Date of Patent: April 6, 2004Assignee: Baylor College of MedicineInventor: Timothy C. Thompson